NocIIOrphan neuropeptide CAS# 188119-47-3 |
- Mibefradil
Catalog No.:BCC1748
CAS No.:116644-53-2
- Mibefradil dihydrochloride
Catalog No.:BCC1749
CAS No.:116666-63-8
- Cilnidipine
Catalog No.:BCC1083
CAS No.:132203-70-4
- Pregabalin
Catalog No.:BCN2175
CAS No.:148553-50-8
- NP118809
Catalog No.:BCC1807
CAS No.:41332-24-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 188119-47-3 | SDF | Download SDF |
| PubChem ID | 90479756 | Appearance | Powder |
| Formula | C92H141N23O28S2 | M.Wt | 2081.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in sterile water | ||
| Sequence | FSEFMRQYLVLSMQSSQ | ||
| SMILES | CC(C)CC(C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)N)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)O)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCSC)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(CC3=CC=CC=C3)N | ||
| Standard InChIKey | PPKKOTLGXBHLAB-XVHSACDVSA-N | ||
| Standard InChI | InChI=1S/C92H141N23O28S2/c1-47(2)38-62(82(133)113-67(44-117)87(138)105-60(34-37-145-8)81(132)102-57(26-30-71(95)122)79(130)112-69(46-119)89(140)114-68(45-118)88(139)106-61(91(142)143)27-31-72(96)123)110-90(141)74(49(5)6)115-85(136)63(39-48(3)4)107-84(135)65(42-52-21-23-53(120)24-22-52)109-77(128)56(25-29-70(94)121)101-76(127)55(20-15-35-99-92(97)98)100-80(131)59(33-36-144-7)104-83(134)64(41-51-18-13-10-14-19-51)108-78(129)58(28-32-73(124)125)103-86(137)66(43-116)111-75(126)54(93)40-50-16-11-9-12-17-50/h9-14,16-19,21-24,47-49,54-69,74,116-120H,15,20,25-46,93H2,1-8H3,(H2,94,121)(H2,95,122)(H2,96,123)(H,100,131)(H,101,127)(H,102,132)(H,103,137)(H,104,134)(H,105,138)(H,106,139)(H,107,135)(H,108,129)(H,109,128)(H,110,141)(H,111,126)(H,112,130)(H,113,133)(H,114,140)(H,115,136)(H,124,125)(H,142,143)(H4,97,98,99)/t54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,74-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Orphan neuropeptide, flanking nociceptin in the precursor pronociceptin. Stimulates locomotion in mice, possibly through a novel specific receptor. |
NocII Dilution Calculator
NocII Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- AWD 131-138
Catalog No.:BCC4045
CAS No.:188116-07-6
- Odoroside H
Catalog No.:BCN1163
CAS No.:18810-25-8
- Abacavir sulfate
Catalog No.:BCC5023
CAS No.:188062-50-2
- Bikinin
Catalog No.:BCC5582
CAS No.:188011-69-0
- Boc-Glu-NH2
Catalog No.:BCC3387
CAS No.:18800-74-3
- 5-Acetyltaxachitriene A
Catalog No.:BCN7412
CAS No.:187988-48-3
- Trp-Lys-Tyr-Met-Val-Met
Catalog No.:BCC5816
CAS No.:187986-17-0
- WKYMVM trifluoroacetate salt
Catalog No.:BCC5815
CAS No.:187986-11-4
- Acetylcorynoline
Catalog No.:BCN1239
CAS No.:18797-80-3
- (+)-Corynoline
Catalog No.:BCN1235
CAS No.:18797-79-0
- Arachidonyl serotonin
Catalog No.:BCC7500
CAS No.:187947-37-1
- Serpentine
Catalog No.:BCN1162
CAS No.:18786-24-8
- H-Ser(tBu)-OH
Catalog No.:BCC3032
CAS No.:18822-58-7
- H-Tyr(tBu)-OH
Catalog No.:BCC3129
CAS No.:18822-59-8
- (±)-Octanoylcarnitine chloride
Catalog No.:BCC6715
CAS No.:18822-86-1
- Methylproamine
Catalog No.:BCC1741
CAS No.:188247-01-0
- (±)-Propionylcarnitine chloride
Catalog No.:BCC6719
CAS No.:18828-58-5
- 8alpha-(2-Methylacryloyloxy)hirsutinolide
Catalog No.:BCN7109
CAS No.:188293-70-1
- Californidine
Catalog No.:BCC8137
CAS No.:18830-99-4
- Massonianoside B
Catalog No.:BCN1164
CAS No.:188300-19-8
- Isodomoic acid G
Catalog No.:BCN1839
CAS No.:188346-81-8
- Pellitorine
Catalog No.:BCN4043
CAS No.:18836-52-7
- MAFP
Catalog No.:BCC7059
CAS No.:188404-10-6
- Paederosidic acid
Catalog No.:BCN3438
CAS No.:18842-98-3
Comparison of behavioural effects of NocII or NocIII, two related pronociceptin-derived peptides.[Pubmed:10622282]
Life Sci. 1999;65(25):2727-33.
Prepronociceptin contains, in addition to nociceptin, other potentially excisable peptides which may have physiological significance. We have here considered NocII, a heptadecapeptide whose sequence lies immediately downstream of that of nociceptin in the precursor polypeptide, as well as NocIII which corresponds to NocII extended by a stretch of three arginine residues. When i.c.v.-administered in mice, NocII (10-10,000 ng) stimulated horizontal locomotor activity and decreased the latency to paw licking but neither to rearing nor escape jumping in the hot plate test (55 degrees C). When nociceptin (100 ng) and NocII (100 ng) were simultaneously intracerebroventricularly injected, each peptide produced its own effect without modifying the effect of the other. NocII was ineffective in the tail flick and writhing tests. NocIII (NocII-Arg-Arg-Arg) was inactive in all tests, even when assayed as long as 40 min following i.c.v. administration. The fact that NocII, but not its very close structural analogue NocII, is biologically active indicates that their may exist a specific receptor to NocII.
Orphan neuropeptide NocII, a putative pronociceptin maturation product, stimulates locomotion in mice.[Pubmed:9106751]
Neuroreport. 1997 Feb 10;8(3):705-7.
NocII is a heptadecapeptide whose sequence lies immediately downstream of nociceptin, the newly discovered natural agonist of the ORL1 receptor, in pronociceptin, nociceptin's precursor polypeptide. Since the sequence of NocII is framed by putative convertase excision sites and it totally conserved across murine and human species, we have sought to determine whether this orphan neuropeptide might by physiologically significant, i.e. endowed with central biological activity in vivo. Intracerebroventricular administration of 10 and 100 ng of NocII increased locomotion in mice. However, unlike nociceptin, which stimulates both the horizontal and vertical (rearing) components of locomotion, NocII affected only the horizontal component. The motor stimulant action of NocII appears to depend largely on dopamine transmission since it is totally reversed by the D1 or the D2 dopamine receptor antagonists SCH 23390 and haloperidol. NocII does not modify the number of explored holes in the hole board test, indicating that, unlike nociceptin, the orphan peptide does not affect exploratory behavior in mice.
